Roivant Sciences Terminates Material Definitive Agreement
Ticker: ROIV · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1635088
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Roivant terminated a big deal. Details TBD.
AI Summary
Roivant Sciences Ltd. announced on October 28, 2024, the termination of a material definitive agreement. The company also filed a Regulation FD Disclosure and Financial Statements and Exhibits as part of this 8-K filing. Specific details regarding the agreement terminated or any financial implications were not provided in the initial filing information.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction, partnerships, and financial performance, requiring investor attention.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's business strategy and potential financial impacts.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- October 28, 2024 (date) — Date of report
FAQ
What was the material definitive agreement that Roivant Sciences Ltd. terminated?
The provided filing information does not specify the details of the material definitive agreement that was terminated.
When was the termination of the material definitive agreement effective?
The filing indicates the report date is October 28, 2024, and the earliest event reported is also October 28, 2024, suggesting the termination was effective on or around this date.
Are there any financial implications disclosed from the termination of this agreement?
The provided filing information does not detail any specific financial implications resulting from the termination of the agreement.
What other items are included in this 8-K filing besides the termination of an agreement?
This 8-K filing also includes a Regulation FD Disclosure and Financial Statements and Exhibits.
Where is Roivant Sciences Ltd. incorporated and what is its principal executive office address?
Roivant Sciences Ltd. is incorporated in Bermuda and its principal executive offices are located at 7th Floor 50 Broadway London SW1H 0DB United Kingdom.
Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 10.2 · Accepted 2024-10-28 16:30:24
Key Financial Figures
- $0.0000000341740141 — ge on which registered Common Shares, $0.0000000341740141 par value per share ROIV The Nasdaq
Filing Documents
- ef20037790_8k.htm (8-K) — 32KB
- ef20037790_ex99-1.htm (EX-99.1) — 28KB
- 0001140361-24-044434.txt ( ) — 204KB
- roiv-20241028.xsd (EX-101.SCH) — 4KB
- roiv-20241028_lab.xml (EX-101.LAB) — 21KB
- roiv-20241028_pre.xml (EX-101.PRE) — 16KB
- ef20037790_8k_htm.xml (XML) — 4KB
02
Item 1.02. Termination of a Material Definitive Agreement. As contemplated by the Merger Agreement, concurrently with the closing of the Merger, Dermavant repaid all amounts outstanding or otherwise payable (including accrued interest and all premiums and exit fees) pursuant to the Credit Agreement, dated as of May 14, 2021 and amended as of May 24, 2024, by and among Dermavant, certain subsidiaries of Dermavant, XYQ Luxco S. R.L. and U.S. Bank Trust Company, National Association (the "Credit Agreement") and terminated the Credit Agreement in accordance with its terms . The information set forth in the Introductory Note to this Current Report on Form 8-K is incorporated by reference into this Item 1.02.
01
Item 7.01. Regulation FD Disclosure. On October 28, 2024, the Company and Organon issued a joint press release announcing the closing of the Merger. A copy of the joint press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Joint Press Release, dated October 28, 2024. 104 Cover Page Interactive Data File (embedded with Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Matt Maisak Name: Matt Maisak Title: Authorized Signatory Dated: October 28, 2024